These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Okopien B; Cwalina L; Lebek M; Kowalski J; Zielinski M; Wisniewska-Wanat M; Kalina Z; Herman ZS Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837 [TBL] [Abstract][Full Text] [Related]
6. Lipid profiles on fibric-acid derivatives. Capps NE Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370 [No Abstract] [Full Text] [Related]
7. Implication of fibrate therapy for homocysteine. Goffin E; Jamar F; Desager JP; Devuyst O Lancet; 1999 Oct; 354(9185):1209. PubMed ID: 10513738 [No Abstract] [Full Text] [Related]
10. [Antilipemic therapy in dyslipidemias in obese non-insulin-dependent diabetics (ONIDDM)]. Palel G; Coman A; Petrovanu R; Ungureanu D; Cojocaru M Rev Med Chir Soc Med Nat Iasi; 1997; 101(3-4):120-2. PubMed ID: 10756782 [TBL] [Abstract][Full Text] [Related]
11. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Schonfeld G Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018 [TBL] [Abstract][Full Text] [Related]
12. Differential associations of statin and fibrate treatment with carotid arterial remodeling. Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285 [TBL] [Abstract][Full Text] [Related]
13. Effects of fibric acid derivatives on biliary lipid composition. Palmer RH Am J Med; 1987 Nov; 83(5B):37-43. PubMed ID: 3318452 [TBL] [Abstract][Full Text] [Related]
14. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS. Francik R; Kryczyk J; Francik S Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274 [TBL] [Abstract][Full Text] [Related]
15. Fibrates and renal function. Gajdos M; Dzúrik R Clin Nephrol; 2003 Jul; 60(1):65-6. PubMed ID: 12872864 [No Abstract] [Full Text] [Related]
16. Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates. Muls E; Van Gaal L; Autier P; Vansant G Int J Obes Relat Metab Disord; 1997 Feb; 21(2):155-8. PubMed ID: 9043971 [TBL] [Abstract][Full Text] [Related]
17. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. Wi J; Kim JY; Park S; Kang SM; Jang Y; Chung N; Shim WH; Cho SY; Lee SH Atherosclerosis; 2010 Nov; 213(1):235-40. PubMed ID: 20855072 [TBL] [Abstract][Full Text] [Related]